Evidence map›Paper›PMID 39582358›Full record

ArticleMolecular oncology2024

Understanding brain cancer and exploiting its vulnerabilities.

Paolo Salomoni

Abstract readEditorial
In one paragraph

Article in Molecular oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Paolo SalomoniNuclear Function Group, German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.ORCID 0000-0001-6885-8116

Funding

Deutsche KrebshilfeDeutsches Zentrum für Luft- und RaumfahrtDeutsches Zentrum für Neurodegenerative Erkrankungen
6 · The paper itself

Abstract

Brain cancer is one of the most devastating neoplasms affecting both children and adults. Its dismal prognosis has for long-time discouraged research in this area. However, in the last 10-15 years remarkable progress has been made in our understanding of brain cancer biology, thus showing promise for the identification of new ways to treat these tumors towards the improvement of patients' survival and quality of life. This Thematic Issue on Brain cancers offers a much needed and timely critical overview of the fundamental discoveries in this area of research and which of those are more promising for effective translation into the clinic. Critically, many Reviews from this Issue also provide discussion points on why the field has not progressed as much as it had hoped to. It is important to emphasize however that we are living in exciting times with regards to our ability to translate fundamental findings into the clinic thanks to the enormous technological advances facilitating the study of cancer genomes and the development of new drugs or repurposing existing agents.

Indexed as

Brain NeoplasmsAnimalsHumans

Identifiers

PMID39582358
PMCPMC11619798

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.